B. Riley Financial Issues Positive Forecast for Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its target price raised by B. Riley Financial from $101.00 to $123.00 in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other research firms also recently weighed in on ARWR. Weiss Ratings downgraded shares of Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Wednesday, May 20th. Chardan Capital raised their price objective on Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. HC Wainwright lifted their price objective on Arrowhead Pharmaceuticals from $100.00 to $115.00 and gave the company a “buy” rating in a report on Monday. Royal Bank Of Canada increased their target price on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Finally, Stifel Nicolaus began coverage on Arrowhead Pharmaceuticals in a research note on Tuesday, July 14th. They issued a “buy” rating and a $98.00 price target for the company. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $96.92.

Arrowhead Pharmaceuticals Trading Up 1.3%

Shares of Arrowhead Pharmaceuticals stock opened at $87.32 on Thursday. Arrowhead Pharmaceuticals has a 52-week low of $15.01 and a 52-week high of $95.49. The stock has a market cap of $12.30 billion, a PE ratio of -40.61 and a beta of 1.26. The firm has a 50-day moving average of $78.84 and a 200-day moving average of $70.57. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The business had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. During the same quarter in the previous year, the company earned $2.75 EPS. The business’s revenue was down 86.4% on a year-over-year basis. As a group, sell-side analysts forecast that Arrowhead Pharmaceuticals will post -3.08 EPS for the current year.

Insider Buying and Selling

In other news, Director Hongbo Lu sold 2,970 shares of the stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total value of $228,333.60. Following the completion of the transaction, the director owned 52,012 shares of the company’s stock, valued at approximately $3,998,682.56. This represents a 5.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARWR. Carolina Wealth Advisors LLC boosted its position in Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 154 shares in the last quarter. Allied Private Wealth LLC bought a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at $43,000. Assenagon Asset Management S.A. boosted its holdings in shares of Arrowhead Pharmaceuticals by 243.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 201,927 shares of the biotechnology company’s stock valued at $16,459,000 after acquiring an additional 143,192 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 15.9% during the 2nd quarter. GAMMA Investing LLC now owns 3,879 shares of the biotechnology company’s stock valued at $316,000 after acquiring an additional 532 shares in the last quarter. Finally, Harbor Investment Advisory LLC bought a new stake in Arrowhead Pharmaceuticals during the 2nd quarter worth $105,000. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals News Roundup

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: B. Riley raises target to $123: B. Riley Financial lifted its price target from $101 to $123 and initiated or reiterated a Buy rating. The new target represents approximately 40.9% upside from the referenced share price, signaling increased confidence in Arrowhead’s pipeline and future commercial potential. Benzinga article
• Positive Sentiment: Upcoming cardiometabolic milestones strengthen the bull case: A report highlights the potential impact of dual Phase 3 milestones involving Arrowhead’s RNAi cardiometabolic programs. Successful clinical progress could materially improve the company’s long-term growth outlook and serve as a catalyst for the stock. The Bull Case For Arrowhead Pharmaceuticals Could Change Following Dual Phase 3 RNAi Cardiometabolic Milestones
• Positive Sentiment: HC Wainwright raises long-term earnings forecasts: HC Wainwright increased its EPS projections for fiscal 2027 through 2030, including a reduction in the expected 2029 loss to $0.80 per share from $1.09 and a forecast of $4.64 EPS in 2030 versus $3.06 previously. The firm maintains a Buy rating and a $115 price target, reflecting expectations for improving profitability as Arrowhead’s programs advance. HC Wainwright Has Bullish Estimate for ARWR Q4 Earnings
• Positive Sentiment: Analyst price-target upgrade: HC Wainwright separately boosted its Arrowhead price target to $115 from its prior target, maintaining its Buy recommendation. HC Wainwright Boosts Arrowhead Pharmaceuticals Price Target to $115

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.